Sundial Growers Inc. (Sundial) and the University of Saskatchewan (U of S) have signed a three-year memorandum of understanding (MOU) to undertake collaborative research exploring opportunities for clinical testing and other research activities that support the advancement of cannabis-related health solutions.
As part of the collaboration, Sundial and the U of S have agreed to undertake clinical trials to study the efficacy of cannabis as a treatment for dementia.
“With our wide-ranging multidisciplinary expertise and cutting-edge plant genomics research, the U of S is eager to work with Sundial to uncover the full potential of cannabis for health and economic benefits,” said said Karen Chad, U of S Vice-President Research.
“This unique study is the first step in our exciting collaboration, and will no doubt position the U of S as a national leader in advancing cannabis as a treatment for dementia.”
The randomized and placebo-controlled, blinded dose-escalation study will take place at two extended